Goldwasser F - Search Results

1

Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.

Wasserman E, Cuvier C, Lokiec F, Goldwasser F, Kalla S, Méry-Mignard D, Ouldkaci M, Besmaine A, Dupont-André G, Mahjoubi M, Marty M, Misset JL, Cvitkovic E. Wasserman E, et al. Among authors: goldwasser f. J Clin Oncol. 1999 Jun;17(6):1751-9. doi: 10.1200/JCO.1999.17.6.1751. J Clin Oncol. 1999. PMID: 10561212 Clinical Trial.

2

[Adamantinoma of the proximal end of the tibia. A case].

Brain EC, Raymond E, Goldwasser F, Extra JM, Marty M. Brain EC, et al. Among authors: goldwasser f. Presse Med. 1994 Oct 29;23(33):1522-6. Presse Med. 1994. PMID: 7824479 Review. French.

3

[Metastatic eye neoplasms. Review of the literature apropos of 4 cases].

Raymond E, Walter S, Goldwasser F, Espie M, Cuvier C, Extra JM, Marty M. Raymond E, et al. Among authors: goldwasser f. Rev Med Interne. 1994 May;15(5):318-24. doi: 10.1016/s0248-8663(05)81437-7. Rev Med Interne. 1994. PMID: 8059156 Review. French.

4

Paclitaxel (Taxol)-associated junctional tachycardia.

Faivre S, Goldwasser F, Soulié P, Misset JL. Faivre S, et al. Among authors: goldwasser f. Anticancer Drugs. 1997 Aug;8(7):714-6. doi: 10.1097/00001813-199708000-00011. Anticancer Drugs. 1997. PMID: 9311449

5

Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports.

Wasserman E, Myara A, Lokiec F, Goldwasser F, Trivin F, Mahjoubi M, Misset JL, Cvitkovic E. Wasserman E, et al. Among authors: goldwasser f. Ann Oncol. 1997 Oct;8(10):1049-51. doi: 10.1023/a:1008261821434. Ann Oncol. 1997. PMID: 9402181 Free article.

6

Re: Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.

Cvitkovic E, Marty M, Wasserman E, Cuvier C, Goldwasser F, Misset JL. Cvitkovic E, et al. Among authors: goldwasser f. J Natl Cancer Inst. 1998 Jul 1;90(13):1016-7. doi: 10.1093/jnci/90.13.1016. J Natl Cancer Inst. 1998. PMID: 9665154 No abstract available.

7

Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line.

Goldwasser F, Bozec L, Zeghari-Squalli N, Misset JL. Goldwasser F, et al. Anticancer Drugs. 1999 Feb;10(2):195-201. doi: 10.1097/00001813-199902000-00008. Anticancer Drugs. 1999. PMID: 10211550

8

Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients.

Goldwasser F, Buthaud X, Gross M, Bleuzen P, Cvitkovic E, Voinea A, Jasmin C, Romain D, Misset JL. Goldwasser F, et al. Anticancer Drugs. 1999 Mar;10(3):263-5. doi: 10.1097/00001813-199903000-00002. Anticancer Drugs. 1999. PMID: 10327030 Clinical Trial.

9

Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.

Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F. Zeghari-Squalli N, et al. Among authors: goldwasser f. Clin Cancer Res. 1999 May;5(5):1189-96. Clin Cancer Res. 1999. PMID: 10353756

10

Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.

Gornet JM, Azoulay D, Lévi F, Yovine A, Misset JL, Goldwasser F. Gornet JM, et al. Among authors: goldwasser f. Anticancer Drugs. 2000 Apr;11(4):263-8. doi: 10.1097/00001813-200004000-00006. Anticancer Drugs. 2000. PMID: 10898541

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

339 results

Search Page

Filters